⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
TORNTPHARM - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.2
| Stock Code | TORNTPHARM | Market Cap | 1,45,237 Cr. | Current Price | 4,292 ₹ | High / Low | 4,483 ₹ |
| Stock P/E | 65.0 | Book Value | 250 ₹ | Dividend Yield | 0.75 % | ROCE | 27.8 % |
| ROE | 26.2 % | Face Value | 5.00 ₹ | DMA 50 | 4,168 ₹ | DMA 200 | 3,781 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.12 % | PAT Qtr | 584 Cr. | PAT Prev Qtr | 606 Cr. |
| RSI | 51.4 | MACD | 57.5 | Volume | 2,43,707 | Avg Vol 1Wk | 4,03,393 |
| Low price | 3,075 ₹ | High price | 4,483 ₹ | PEG Ratio | 2.67 | Debt to equity | 0.25 |
| 52w Index | 86.4 % | Qtr Profit Var | 20.4 % | EPS | 65.0 ₹ | Industry PE | 27.6 |
📊 Technical Analysis
- Chart Patterns: Stock is trading above 50 DMA (₹4,168) and 200 DMA (₹3,781), showing strength. Support at ₹4,168, resistance around ₹4,400–₹4,483.
- Moving Averages: Current price (₹4,292) is above both averages, confirming bullish bias.
- RSI: 51.4 — neutral to slightly bullish, suggesting balanced momentum.
- MACD: 57.5 — bullish crossover, momentum positive.
- Bollinger Bands: Price near upper band, showing strong buying interest.
- Volume Trends: Current volume (2.43L) below 1-week average (4.03L), suggesting reduced participation but steady accumulation.
📈 Momentum & Signals
- Short-term Momentum: Strong with bullish MACD and RSI above 50.
- Entry Zone: ₹4,200–₹4,250 (near support).
- Exit Zone: ₹4,400–₹4,483 (first resistance), ₹4,550 (next resistance).
- Trend Status: Trending upward with bullish signals; reversal risk only if price falls below ₹4,168.
✅ Positive
- Strong EPS at ₹65.0, reflecting profitability.
- ROE at 26.2% and ROCE at 27.8% show excellent efficiency.
- Low debt-to-equity ratio (0.25) indicates financial stability.
- PEG ratio at 2.67 suggests reasonable valuation relative to growth.
⚠️ Limitation
- High P/E ratio (65.0) compared to industry PE (27.6), indicating premium valuation.
- Quarterly PAT slightly declined (₹584 Cr vs ₹606 Cr), showing earnings volatility.
- DII holdings decreased by -0.12%, reflecting cautious domestic sentiment.
📰 Company Negative News
- PAT declined marginally compared to previous quarter, raising concerns about earnings consistency.
- Stock corrected from 52-week high of ₹4,483 to current ₹4,292.
🌟 Company Positive News
- Quarterly profit variation at 20.4% shows operational resilience.
- FII holdings increased by 0.21%, reflecting foreign investor confidence.
- Strong fundamentals with high ROE/ROCE and low debt.
🏭 Industry
- Industry PE at 27.6, much lower than company PE (65.0), indicating TORNTPHARM trades at a premium.
- Pharmaceutical sector remains strong with consistent demand and global expansion opportunities.
🔎 Conclusion
- TORNTPHARM is trending upward with strong technical signals.
- Short-term traders may consider entry near ₹4,200–₹4,250 with exit around ₹4,400–₹4,483.
- Breakout above ₹4,483 could trigger rally towards ₹4,550.
- Long-term investors should weigh premium valuation against strong fundamentals and sector growth potential.